Reckitt Benckiser (RKT) Fair Value: 35% Upside

Reckitt Benckiser Group PLC Fair Value Analysis

Reckitt Benckiser Group PLC (RKT.L) currently trades at GBP 50.18. Our proprietary valuation model places its fair value at GBP 67.78, implying 35.1% upside. With a Quality Score of 69/100, the consumer staples company appears undervalued on a multi-model basis.

What Reckitt Benckiser Does

Reckitt Benckiser is a global leader in consumer health and hygiene. Its portfolio spans two main segments: Health (Mucinex, Gaviscon, Strepsils) and Hygiene (Dettol, Lysol, Harpic, Finish). These Powerbrands drive the majority of sales in both mature Western markets and fast-growing emerging economies.

Why Our Model Shows Undervaluation

Multiple valuation approaches converge on GBP 67.78. The discount reflects short-term headwinds in Europe and a soft cold-and-flu season, yet long-term cash-flow forecasts support a higher intrinsic value. Emerging-market momentum and continued brand innovation are key positive drivers embedded in the model.

Recent Performance and Market Context

Q1 2026 results showed Core Reckitt like-for-like revenue growth of 1.3%, with high-single-digit gains in emerging markets offsetting softer developed-market trends. Management kept full-year guidance unchanged at +4% to +5% LFL for the core business. Half-year results are scheduled for 29 July 2026.

Analyst fair-value estimates from other sources sit in the low-to-mid £60s, broadly consistent with our conclusion that the shares offer meaningful upside from current levels.

Key Valuation Drivers

• Resilient brand equity and pricing power in essential categories.
• Accelerating growth in China, India and other emerging markets.
• Pipeline of innovation, including new Mucinex formulations.
• Attractive dividend yield supported by strong free-cash-flow conversion.

Check Reckitt Benckiser Group PLC on our fair value calculator to see how different assumptions affect the outcome.

Main Risks to Consider

• Continued weakness in European categories and seasonal OTC volatility.
• Regulatory scrutiny on health and hygiene claims.
• Currency translation and geopolitical risks in emerging markets.
• Intense competition from private-label alternatives.

Balanced Verdict

Reckitt Benckiser combines defensive consumer staples characteristics with attractive emerging-market exposure. At GBP 50.18 the shares trade at a clear discount to our calculated fair value of GBP 67.78. While near-term trading conditions remain challenging, the long-term growth trajectory and brand strength support the view that the stock is undervalued today.

Investors seeking a data-driven view of valuation can explore the free Fair Value Calculator to run their own scenarios on Reckitt Benckiser Group PLC and thousands of other stocks.

Frequently Asked Questions

Is Reckitt Benckiser undervalued at current prices?

Our model shows Reckitt Benckiser Group PLC trading at £50.18 against a fair value of £67.78, indicating approximately 35% upside potential with a Quality Score of 69/100.

What are the main risks for Reckitt Benckiser stock?

Key risks include weak European demand, seasonal OTC volatility, regulatory pressures on health claims, currency fluctuations in emerging markets, and competition from private-label brands.

How does Reckitt Benckiser generate revenue?

The company earns revenue primarily from its Health and Hygiene portfolios, including iconic brands such as Dettol, Lysol, Harpic and Mucinex, sold across developed and high-growth emerging markets.

Sources

Context gathered via live web search while writing this article:

• https://uk.finance.yahoo.com/news/reckitt-benckiser-shares-slide-amid-115014643.html
• https://simplywall.st/stocks/gb/household/lse-rkt/reckitt-benckiser-group-shares
• https://www.reckitt.com/investors/results-presentations/
• https://www.directorstalkinterviews.com/reckitt-benckiser-reports-q1-2026-growth-and-keeps-full-year-outlook-unchanged/4121249758
• https://valueinvesting.io/RKT.L/valuation/fair-value
• https://people.stern.nyu.edu/adamodar/pdfiles/cfcertificate/sampleprojects/CFSample1.pdf
• https://finance.yahoo.com/markets/stocks/articles/reckitt-benckiser-lse-rkt-stock-140615623.html
• https://www.wsj.com/business/earnings/reckitt-benckiser-raises-outlook-after-adjusted-profit-beats-expectations-9d124c02

Educational analysis only — not financial advice and not a buy or sell recommendation. Valuations are model-based and may be wrong; past performance does not indicate future results.